TECH-MAHINDRA
19.9.2023 16:35:36 CEST | Business Wire | Press release
Tech Mahindra, a leading provider of digital transformation, consulting, and business re-engineering services & solutions, today inaugurated a local innovation centre in Espoo, Finland. This expansion comes after a sustained period of growth in the region and signifies Tech Mahindra’s commitment to further its journey in Finland, and the Nordic region. The new centre will accommodate a diverse workforce – increasing the in-country headcount ranging from experienced business leaders to fresh talent, in collaboration with the local ecosystem.
Located in Espoo, a part of the greater Helsinki metropolitan area, the new centre situates Tech Mahindra at the heart of one of the major business hotspots and innovation hubs in the Nordics. From this strategic location, Tech Mahindra will continue to provide digital business transformation services and solutions to customers.
Mohit Joshi, Managing Director and CEO Designate of Tech Mahindra, said, “Given its focus on innovation, sustainability, and a unique approach to entrepreneurship; today Finland ranks amongst the topmost countries in the world that leverage emerging technologies to shape the future business landscape. This is also reflected in Tech Mahindra’s commitment to the ongoing expansion in the Nordics region, and the establishment of our new centre in Espoo. It is our endeavor to widen the talent pool, fuel innovation, improve agility to deliver robust solutions, and be closer to our customers’ businesses to drive sustainable growth.”
The inauguration ceremony was attended by dignitaries such as Raveesh Kumar, Ambassador of India to Finland; Jusa Susia, Senior Director & Head of Region East Asia & India at Business Finland; and Janne Kari, Head of Industry, ICT and Digitalisation at Invest in Finland. Tech Mahindra representatives include CP Gurnani, Managing Director and CEO; Mohit Joshi, Managing Director and CEO Designate; Mukul Dhyani, Senior Vice President & Business Head Continental Europe; Rajesh Barwal, VP & Country Manager for Sweden and Finland; C-H Hallstrom, Vice President, Strategic Programs, Nordics.
Further to the commitment in 2022 to set up a Makers Lab, Tech Mahindra’s research and development arm in Finland, the newly opened centre will also facilitate innovation in collaboration with new and existing customers in the region. The team will work on new and emerging technologies such as Quantum computing, Generative AI and Metaverse. The Makers Lab will also plug into the local startup ecosystem and universities to provide new opportunities in R&D across industries.
In the ten years since Tech Mahindra entered the Finnish market, the organisation has firmly established itself as a leading business transformation expert in the region. By leveraging deep industry expertise and long-term experience in tailoring and deploying best-in-class solutions, Tech Mahindra continues to help businesses to navigate the complex challenges present in the modern business landscape.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230919543874/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release
The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom